DE69233337D1 - Verwendung von CANP-Inhibitoren in pharmazeutischen Zubereitungen - Google Patents

Verwendung von CANP-Inhibitoren in pharmazeutischen Zubereitungen

Info

Publication number
DE69233337D1
DE69233337D1 DE69233337T DE69233337T DE69233337D1 DE 69233337 D1 DE69233337 D1 DE 69233337D1 DE 69233337 T DE69233337 T DE 69233337T DE 69233337 T DE69233337 T DE 69233337T DE 69233337 D1 DE69233337 D1 DE 69233337D1
Authority
DE
Germany
Prior art keywords
inhibitors
therapy
contraception
neutral
viral diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69233337T
Other languages
English (en)
Other versions
DE69233337T2 (de
Inventor
Helen Logothetou-Rella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69233337D1 publication Critical patent/DE69233337D1/de
Application granted granted Critical
Publication of DE69233337T2 publication Critical patent/DE69233337T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69233337T 1991-06-03 1992-06-02 Verwendung von CANP-Inhibitoren in pharmazeutischen Zubereitungen Expired - Fee Related DE69233337T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR10100238 1991-06-03
GR91100238 1991-06-03
PCT/EP1992/001223 WO1992021373A1 (en) 1991-06-03 1992-06-02 USE OF CANPs-INHIBITORS IN PHARMACEUTICAL PREPARATIONS

Publications (2)

Publication Number Publication Date
DE69233337D1 true DE69233337D1 (de) 2004-05-13
DE69233337T2 DE69233337T2 (de) 2005-05-04

Family

ID=10940713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233337T Expired - Fee Related DE69233337T2 (de) 1991-06-03 1992-06-02 Verwendung von CANP-Inhibitoren in pharmazeutischen Zubereitungen

Country Status (14)

Country Link
EP (1) EP0549742B1 (de)
JP (1) JP3703828B2 (de)
AT (1) ATE263574T1 (de)
AU (1) AU646961B2 (de)
CA (1) CA2088671C (de)
DE (1) DE69233337T2 (de)
DK (1) DK0549742T3 (de)
ES (1) ES2215162T3 (de)
GR (1) GR1001044B (de)
IL (1) IL102079A (de)
NO (1) NO930305L (de)
NZ (1) NZ243003A (de)
PT (1) PT100560A (de)
WO (1) WO1992021373A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3517238B2 (ja) * 1992-09-09 2004-04-12 アムジェン インコーポレイテッド レトロウイルス感染の阻害
US5607831A (en) * 1993-03-25 1997-03-04 The United States Of America As Represented By The Department Of Health And Human Services In vitro methods for assessing the susceptibility of HIV-1-infected individuals to cysteine protease-mediated activation-induced programmed cell death
EP0626178A1 (de) * 1993-05-17 1994-11-30 Ciba-Geigy Ag Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen
US20030060435A1 (en) 1994-05-31 2003-03-27 Serge Carillo Method of cancer treatment by p53 protein control

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815962D0 (en) * 1988-07-05 1988-08-10 Univ London Pharmaceutical preparation & method for promoting reinnervation of muscle fibers

Also Published As

Publication number Publication date
CA2088671C (en) 1997-01-14
CA2088671A1 (en) 1992-12-04
ES2215162T3 (es) 2004-10-01
IL102079A (en) 1996-10-16
NO930305D0 (no) 1993-01-29
ATE263574T1 (de) 2004-04-15
PT100560A (pt) 1993-07-30
EP0549742A1 (de) 1993-07-07
NZ243003A (en) 1997-07-27
EP0549742B1 (de) 2004-04-07
NO930305L (no) 1993-02-26
DK0549742T3 (da) 2004-07-26
JPH06502188A (ja) 1994-03-10
AU1907392A (en) 1993-01-08
GR1001044B (el) 1993-04-28
DE69233337T2 (de) 2005-05-04
JP3703828B2 (ja) 2005-10-05
AU646961B2 (en) 1994-03-10
WO1992021373A1 (en) 1992-12-10

Similar Documents

Publication Publication Date Title
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
BG101118A (en) Therapeutical compounds
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
TR199903053T2 (xx) Benzimidazol t�revleri.
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
BR9910032A (pt) Tienopirimidinas
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
ATE259654T1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
DE69233337D1 (de) Verwendung von CANP-Inhibitoren in pharmazeutischen Zubereitungen
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
DE3786456T2 (de) Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen.
ES2013342A6 (es) Procedimiento para preparar composiciones farmaceuticas a base de ingredientes seleccionados principalmente entre alcohol, fenol, polvo de cantarida, yodo y fosforo.
NO20050067L (no) Pegylert T1249 polypeptid
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
RU95109909A (ru) Способ ингибирования ретровирусной инфекции, ингибитор протеазы, кодирующая его нуклеиновая кислота и способ рекомбинантного продуцирования серинового ингибитора

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee